The Biological Cost of Being Skinny

Описание: Every single piece of information shared in this video is genuine and carefully brought to you after deep and detailed research by our dedicated team. We’ve also included the sources below so you can personally verify everything through Google-recommended references, because your trust truly matters to us.

Thank you from the bottom of our hearts for spending your precious time with us and watching this video. Stay happy, stay healthy, and always keep that beautiful smile on your face.

Never forget—good health is the greatest gift nature has given us, and we pray it always stays with you and your loved ones.
.
.
.
*Trusted Medical Sources & Institutions:*

1. *The New England Journal of Medicine (NEJM):* Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 Trial).
2. *The New England Journal of Medicine (NEJM):* Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial).
3. *JAMA (Journal of the American Medical Association):* *Sodhi M et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss*.
4. *The Lancet:* Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2).
5. *Diabetes Care (American Diabetes Association):* *Bezin J et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer*.
6. *U.S. Food and Drug Administration (FDA):* *Prescribing Information and Medication Guides for Mounjaro (tirzepatide) and Ozempic (semaglutide)*.
7. *American College of Gastroenterology:* *Clinical guidelines and warnings regarding gastroparesis and ileus associated with GLP-1RA use*.
8. *Nature Medicine:* *Penn Medicine study on GLP-1 receptor agonists, food noise, and dopamine reward pathways*.
9. *Journal of Clinical Investigation:* Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (Mechanism of Action).
10. *The American Thoracic Society:* *Research regarding the impact of weight management and GLP-1 therapies on obstructive sleep apnea and metabolic health*.